ArticleCase reports in gastrointestinal medicine2025
Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine.
Article in Case reports in gastrointestinal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dulaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is utilized for the management of type 2 diabetes and obesity, typically administered subcutaneously at a dosage of 0.75 mg/0.5 mL once weekly, with adjustments made as needed. While typically well tolerated, it may induce infrequent yet severe adverse effects, including acute pancreatitis. Case Presentation: In this case report, we present the first documented case of GLP-1-induced pancreatitis in Palestine. A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting. The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy. The patient experienced upper abdominal pain radiating to the back, nausea, and alternating diarrhea and constipation for 5 days. Laboratory investigations revealed elevated serum amylase and lipase levels, and imaging studies confirmed signs of acute pancreatitis. After the GLP-1 agonist was discontinued, the patient's symptoms improved, and she fully recovered. Conclusion: GLP-1 receptor agonists are advantageous for the management of diabetes and obesity but may precipitate acute pancreatitis in predisposed individuals. Clinicians should be aware of this potential risk and promptly investigate any patient who presents with signs of acute abdominal pain during GLP-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.